Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Texas MPN Workshop 2021
🗞️ In a recent paper in @Haematologica, the longest survival to date in any unselected group of patients with #MultipleMyeloma was reported (an average of almost 13 years).
🎥 We caught up with Dr James Berenson (@myelomadoc) to gain insight into the paper & to hear about the…
The longest reported survival to date in any unselected group of patients with multiple myeloma
In this video, James Berenson, MD, Berenson Cancer Center, West Hollywood, CA, discusses the findings of a recently ...
twitter.com
Have you registered for #CART26 yet?🩸
Hear from @ARampotas, who highlights the importance of the meeting as a platform for exchanging ideas & showcasing new data in the field of CAR-T & cellular therapy:
🎥
Click here to register your attendance (in… https://twitter.com/i/web/status/2016844011575652371
The upcoming EBMT-EHA European CAR T-cell meeting 2026: sharing updates in CAR-T & cellular therapy
In this video, Alex Rampotas, MBBS, MRCP, University College London, London, UK, invites viewers to register for the...
ow.ly
At #ASH25, we spoke with the lovely @JenMarvinPeek of @MDAndersonNews, who discussed the association of ASXL1 mutations with adverse outcomes in patients with ELN 2024 favorable-risk AML treated with venetoclax-containing low-intensity therapy.
Watch here: 👉…
Impact of ASXL1 mutations in favorable risk AML treated with ven-containing low-intensity therapy
Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the association of...
twitter.com
We recently spoke with Jacob Soumerai (@MassGeneralNews), who shared the latest updates in cellular therapy for CLL, highlighted a real-world evidence analysis of liso-cel, & outlined potential strategies to improve upon CD19-directed #CARTCell therapy.
Click to watch:
🎥…
Latest updates in cell therapy for CLL: real-world insights and strategies to improve CAR-T therapy
Jacob Soumerai, MD, Massachusetts General Hospital, Boston, MA, discusses the latest updates in cellular therapy for c...
twitter.com
🚨 LAST CHANCE TO REGISTER for our ASH 2025 #MPN Highlights webinar taking place TOMORROW
Join Prof. @harrisoncn1, Dr Francesca Palandri & Dr John Mascarenhas for the Post ASH 2025 Highlights: MPN Webinar🩸🔬
🗓️ Thursday 29 January | 10:00 – 12:00 CST/ 16:00 – 18:00 GMT/ 17:00…
Welcome! You are invited to join a webinar: Post-ASH 2025 MPNs highlights webinar. After register...
Join us to watch leading MPNs experts present summaries on the most significant abstracts from ASH 2025 followed b...
twitter.com
Texas MPN Workshop 2021
🗞️ In a recent paper in @Haematologica, the longest survival to date in any unselected group of patients with #MultipleMyeloma was reported (an average of almost 13 years).
🎥 We caught up with Dr James Berenson (@myelomadoc) to gain insight into the paper & to hear about the…
The longest reported survival to date in any unselected group of patients with multiple myeloma
In this video, James Berenson, MD, Berenson Cancer Center, West Hollywood, CA, discusses the findings of a recently ...
twitter.com
Have you registered for #CART26 yet?🩸
Hear from @ARampotas, who highlights the importance of the meeting as a platform for exchanging ideas & showcasing new data in the field of CAR-T & cellular therapy:
🎥
Click here to register your attendance (in… https://twitter.com/i/web/status/2016844011575652371
The upcoming EBMT-EHA European CAR T-cell meeting 2026: sharing updates in CAR-T & cellular therapy
In this video, Alex Rampotas, MBBS, MRCP, University College London, London, UK, invites viewers to register for the...
ow.ly
At #ASH25, we spoke with the lovely @JenMarvinPeek of @MDAndersonNews, who discussed the association of ASXL1 mutations with adverse outcomes in patients with ELN 2024 favorable-risk AML treated with venetoclax-containing low-intensity therapy.
Watch here: 👉…
Impact of ASXL1 mutations in favorable risk AML treated with ven-containing low-intensity therapy
Jennifer Marvin-Peek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the association of...
twitter.com
We recently spoke with Jacob Soumerai (@MassGeneralNews), who shared the latest updates in cellular therapy for CLL, highlighted a real-world evidence analysis of liso-cel, & outlined potential strategies to improve upon CD19-directed #CARTCell therapy.
Click to watch:
🎥…
Latest updates in cell therapy for CLL: real-world insights and strategies to improve CAR-T therapy
Jacob Soumerai, MD, Massachusetts General Hospital, Boston, MA, discusses the latest updates in cellular therapy for c...
twitter.com
🚨 LAST CHANCE TO REGISTER for our ASH 2025 #MPN Highlights webinar taking place TOMORROW
Join Prof. @harrisoncn1, Dr Francesca Palandri & Dr John Mascarenhas for the Post ASH 2025 Highlights: MPN Webinar🩸🔬
🗓️ Thursday 29 January | 10:00 – 12:00 CST/ 16:00 – 18:00 GMT/ 17:00…
Welcome! You are invited to join a webinar: Post-ASH 2025 MPNs highlights webinar. After register...
Join us to watch leading MPNs experts present summaries on the most significant abstracts from ASH 2025 followed b...
twitter.com
